Xintela AB
1XT
Company Profile
Business description
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin α10β1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
Contact
Medicon Village
Lund223 81
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Undervalued REIT receives offer from PE firm
Our analysts’ view on the value of the unsolicited offer.
stocks
Apple: With launch of foldable iPhone duo things look twice as nice
We’ve raised our fair value estimate of Apple stock.
stocks
What did Morningstar subscribers buy and sell during August?
Earnings season fuels trading activity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,920.20 | 13.80 | 0.15% |
| CAC 40 | 8,179.77 | 63.01 | 0.78% |
| DAX 40 | 25,568.56 | 207.41 | 0.82% |
| Dow JONES (US) | 52,573.29 | 509.19 | 0.98% |
| FTSE 100 | 10,650.44 | 41.52 | 0.39% |
| HKSE | 24,805.63 | 148.84 | -0.60% |
| NASDAQ | 26,333.04 | 251.31 | 0.96% |
| Nikkei 225 | 64,011.34 | 1,259.61 | -1.93% |
| NZX 50 Index | 13,580.33 | 130.68 | -0.95% |
| S&P 500 | 7,656.98 | 65.28 | 0.86% |
| S&P/ASX 200 | 8,741.20 | 23.30 | 0.27% |
| SSE Composite Index | 3,888.11 | 46.29 | -1.18% |